Press Release
Will Hash Power Mining Lead Ethereum Into 2.0?
2020 is destined to be an extraordinary year. The global health problems brought about by the Corona-virus, had not only accelerated fluctuation in personal assets, but also intensified the turbulence of the capital market. The first thing that bears the brunt is the US dollar system as the global currency, followed by crude oil, stocks, etc. At this time, the outstanding performance of cryptocurrencies has attracted the attention of many traditional investors, and the concept of “mainstream cryptocurrencies as safe-haven assets” was mentioned again.
From the perspective of M1, bitcoin is now recognized as the sixth largest currency in the world, which indicates that cryptocurrencies have officially integrated into the global mainstream financial system.
In 2020, the world’s largest digital payment platform PayPal announced that it will soon be able to let its more than 1 billion users to trade cryptocurrencies such as BTC, ETH through its online wallet.
In 2020, a financial services company led by Jack Dorsey, CEO of the digital payment company Square, announced that it had bought 4,709 BTC worth $50 million, which accounted for 1% of the company’s total assets.
In 2020, Singapore’s largest retail and commercial bank — DBS Bank, will soon launch the DBS cryptoexchange, which will support Bitcoin (BTC), Ethereum (ETH), Ripple (XRP), and Bitcoin Cash (BCH) to start with.
In 2020, Ethereum settlement exceeded 1 trillion USD, surpassing the Bitcoin network settlement amount for the first time.
In 2020, the ecological market value of Ethereum has exceeded 100 billion USD, and the total lock-up amount of the Ethereum DeFi project has exceed 10 billion USD, which is a tenfold increase compared to 2019.
In 2020, the concept of DeFi made an explosion in the blockchain industry. Until late august, the total market value of all Defi tokens has reached 11.5 billion USD, the trading volume of decentralized cryptoexchanges has exceeded 400 million USD, and the total lock up value of DeFi projects has raised over 6.2 billion USD.
Moreover, the data above came from the current congestion and the racket high gas fee of ETH . After Ethereum 2.0 is fully launched, the TPS of Ethereum said to be increasing from 10-25 TPS to 100,000 TPS, and the market value of Ethereum ecosystem will reach trillions of dollars.
Although there are many complaints about the Ethereum network now, among the 242 DeFi projects, 197 are deployed on Ethereum, while EOS and Bitcoin have only 22 and 23 DeFi projects respectively.
With the increasing scale of the Ethereum DeFi ecosystem, the governance rights will be handed over to the community more and more, which makes migration basically impossible. This situation makes Ethereum and DeFi pushing each other’s mutual achievements.
From investors’ perspective, having experienced the collapse of ICO and many other incidents, it may be difficult for them to establish trust in centralized crypto-projects again.
In this context, the Galaxy Cloud hash power mining platform is a decentralized asset management platform that integrates ETH 1.0 POW mining , ETH 2.0 POS cloud mining and DeFi liquid mining, and is constructed to achieve tens of trillions of dollars of market value of ETH 2.0 in the future!
Galaxy Cloud hash power mining platform is created by the Galaxy Cloud Foundation. Galaxy Cloud Foundation was branched from Singapore AI Foundation in May 2020, aiming to support the research and development of various blockchain software and hardware, among which Ethereum and the decentralized technology ecosystem are the main targets.
Since the establishment of Singapore AI Foundation in 2017, it has been committed to support the research and development of artificial intelligence, and the return on their investment projects has been at the leading level of the AI industry. At the beginning of 2020, the AI Foundation decided to put out some funds and personnel to establish a blockchain fund to help the development of the emerging technology industries, and there came Galaxy Cloud Foundation.
The mission of Galaxy Cloud Foundation is to promote the development of new technologies and applications, especially in the field of new open and decentralized hardware and software architectures. Its goal is to develop, cultivate, promote and maintain decentralized and open technologies.
Galaxy Cloud Foundation gathers the world’s top financial technology talents, through years of research and development, formed the world’s leading artificial intelligence DeFi asset management platform — Galaxy Cloud hash power mining platform. Based on the global DeFi alliance (including Uniswap, MakerDao, Debank and dozens of other DeFi platforms), it integrated ETH 1.0 POW mining, ETH 2.0 POS cloud mining and DEFI liquidity mining. The Galaxy Cloud hash power mining platform will become the benchmark application of the future DeFi ecology, helping to build an application ecology with a market value of 10 trillion US dollars for ETH 2.0 for the next ten years.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
SHENZHEN, CHINA – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke.
With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms.
Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals.
The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients.
More Information about Y-3 for Injection
The pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects.
The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability.
On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent.
About Stroke
According to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference
- National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001.
- Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Worcester, Massachusetts, 11 Dec 2025, ZEX PR WIRE, As debates over privacy, free speech, and policing continue to unfold nationwide, local residents like Kevin Wall of Worcester are encouraging more community awareness around civil liberties and individual rights.
Wall, who has lived in Worcester for over a decade, says many people care about these issues but don’t always know where to start. “Most people I talk to want things to be fair and transparent,” Kevin Wall said. “They’re concerned about surveillance, about how schools handle discipline, about what kind of data companies and the government collect. But they don’t always feel equipped to speak up.”
Though not affiliated with any organization, Wall often shares resources from civil rights groups like the ACLU, especially those related to Massachusetts policies and digital rights. He follows court decisions and legislative changes and encourages others to do the same. “You don’t have to be an expert. Just being informed helps you spot when something isn’t right.”
In Massachusetts, recent civil liberties conversations have included facial recognition technology bans, school-based surveillance tools, bail reform, and expanded voting access. Organizations like the ACLU of Massachusetts have weighed in on many of these issues, publishing legal analysis and policy recommendations.
Worcester itself has seen growing interest in these topics. In recent years, the city has hosted forums on data privacy, transparency in school policies, and police oversight. Wall sees this as a sign of a more engaged public. “It’s not about being political,” he said. “It’s about understanding how systems work and making sure people are treated fairly.”
He says the rise of AI and digital tracking tools has made the public role more important than ever. “The tools are changing fast. You need people who are paying attention and asking questions.”
Wall is particularly focused on issues that affect everyday life: student discipline policies, use of technology in public spaces, and due process protections in local courts. “You can’t protect your rights if you don’t know what they are,” he said. “Groups like the ACLU do a good job breaking it down.”
For Worcester residents looking to get more involved, Wall recommends starting small. “Read a case summary. Sign up for an email list. Go to a local meeting. Even asking questions at a school board or city council meeting makes a difference.”
While he doesn’t speak publicly or run a group, Wall believes that quiet civic engagement still matters. “There are lots of ways to contribute without being front and center.”
He hopes more residents in Worcester will take interest in how rights are shaped and protected at the local level. “We all benefit when more people pay attention. Whether it’s about speech, privacy, education, or equal treatment, these issues affect all of us.”
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Kevin Wall Worcester: Local Voices Add Perspective as Civil Liberties Take Center Stage
Worcester, Massachusetts, 11 Dec 2025, ZEX PR WIRE, From school board meetings to courtroom challenges, the conversation around civil liberties in America is evolving. In cities like Worcester, residents such as Kevin Wall are quietly helping keep those conversations alive.
Wall isn’t a politician or spokesperson. He’s a longtime Worcester resident who takes an active interest in civil rights and regularly shares articles and legal updates with friends and neighbors. He says staying informed is part of being a responsible member of the community. “It’s not about having all the answers,” he said. “It’s about knowing enough to ask the right questions.”
Across the country, major civil liberties issues are in the spotlight—digital surveillance, student speech, reproductive rights, and access to public records among them. The ACLU and other legal groups continue to play a key role in shaping public understanding and defending constitutional protections.
Wall keeps tabs on this work, particularly from the ACLU of Massachusetts. “They’re one of the groups that actually explains things in plain language,” he said. “I follow their email briefings and court updates.”
In Worcester, topics like facial recognition, police transparency, and equity in school discipline have generated local interest. Wall believes these conversations are healthier when more people feel empowered to participate. “When you understand your rights, you’re more likely to speak up,” he said. “And when regular people speak up, public systems tend to work better.”
Although Wall doesn’t attend public events or speak on panels, his role is more grassroots. He brings up civil liberties topics in everyday conversation and encourages others to learn more. “People are surprised by how much these things touch their lives—how a policy might affect their kid at school or the way local police handle data.”
He’s especially concerned about how fast technology is changing the landscape. “AI tools, data collection, automated decisions—these are things that need public oversight,” Wall said. “You don’t need to be paranoid, but you should know what’s happening.”
Wall represents a growing number of residents who take an interest in public life without making it their job. “Not everyone wants to go to rallies or run for office,” he said. “But that doesn’t mean they don’t care. Being informed is a kind of participation.”
The ACLU continues to advocate for strong protections around voting access, LGBTQ+ rights, free expression, and immigration policy—many of which have direct implications for Worcester residents. Wall believes that raising awareness is a shared responsibility. “Organizations can only do so much. People need to take that extra step—read more, talk more, think more critically.”
As legal and political battles continue across the country, local voices like Kevin Wall’s reflect a broader truth: civil liberties aren’t just an issue for lawyers and lawmakers. They belong to everyone. And in Worcester, more residents are starting to take notice.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
Kevin Wall Worcester: Local Voices Add Perspective as Civil Liberties Take Center Stage
Kevin Wall of Worcester Encourages Greater Civic Engagement Around Civil Liberties
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release5 days ago
Author of Journey to Forever Meets with Film Producer to Discuss Screen Potential
-
Press Release5 days ago
The Attic Insulation Specialists Inc. Expands Full-Service Home Energy and Safety Solutions Across Southern California
-
Press Release5 days ago
Jack Botanicals Sets New Industry Standard with Premium Quality Kratom and Best Kratom Vendor
-
Press Release6 days ago
Operational Police Protective Services Introduces Elite Security Solutions for High-Profile Corporate and Entertainment Events
-
Press Release6 days ago
Bougainville Launches Offshore Gaming and Financial Authorities
-
Press Release6 days ago
Mary Drucker Palm Beach Dental Assistant Champions Oral Health Through Local Outreach
-
Press Release5 days ago
NUICC Launches South India Regional Chamber in Bengaluru to Propel U.S.–India Trade and Innovation
-
Press Release5 days ago
Safari Soles Tours Reaches 2,000th 5-Star Review on Tripadvisor and Becomes Best Rated Safari Operator in Tanzania